Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020

DelveInsight Business Research LLP

“Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Benign prostatic hyperplasia (BPH) market. A detailed picture of the Benign prostatic hyperplasia (BPH) pipeline landscape is provided, which includes the disease overview and Benign prostatic hyperplasia (BPH) treatment guidelines.

The assessment part of the report embraces in-depth Benign prostatic hyperplasia (BPH) commercial assessment and clinical assessment of the Benign prostatic hyperplasia (BPH) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Benign prostatic hyperplasia (BPH) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Scope of the report

• The Benign prostatic hyperplasia (BPH) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Benign prostatic hyperplasia (BPH) across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Benign prostatic hyperplasia (BPH) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
• Detailed Benign prostatic hyperplasia (BPH) research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Benign prostatic hyperplasia (BPH).

Report highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Benign prostatic hyperplasia (BPH).    
• In the coming years, the Benign prostatic hyperplasia (BPH) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 
• The companies and academics that are working to assess challenges and seek opportunities that could influence Benign prostatic hyperplasia (BPH) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Benign prostatic hyperplasia (BPH) treatment market. Several potential therapies for Benign prostatic hyperplasia (BPH) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Benign prostatic hyperplasia (BPH) market size in the coming years.  
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Benign prostatic hyperplasia (BPH)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Request for sample pages: https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-pipeline-insight

Table of contents:

1. Report Introduction

2. Benign prostatic hyperplasia (BPH) 

2.1. Overview

2.2. History 

2.3. Benign prostatic hyperplasia (BPH) Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. Benign prostatic hyperplasia (BPH) Diagnosis 

2.6.1. Diagnostic Guidelines

3. Benign prostatic hyperplasia (BPH) Current Treatment Patterns

3.1. Benign prostatic hyperplasia (BPH) Treatment Guidelines

4. Benign prostatic hyperplasia (BPH) – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Benign prostatic hyperplasia (BPH) companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Benign prostatic hyperplasia (BPH) Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. Benign prostatic hyperplasia (BPH) Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. Benign prostatic hyperplasia (BPH) Late Stage Products (Phase-III)

7. Benign prostatic hyperplasia (BPH) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Benign prostatic hyperplasia (BPH) Discontinued Products

13. Benign prostatic hyperplasia (BPH) Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report? 

14. Benign prostatic hyperplasia (BPH) Key Companies

15. Benign prostatic hyperplasia (BPH) Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Benign prostatic hyperplasia (BPH) Unmet Needs

18. Benign prostatic hyperplasia (BPH) Future Perspectives

19. Benign prostatic hyperplasia (BPH) Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/